Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 14 full-time employees. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
How did SNGX's recent EPS compare to expectations?
The most recent EPS for Soligenix Inc is $-0.28, not beating expectations of $-0.28.
How did Soligenix Inc SNGX's revenue perform in the last quarter?
Soligenix Inc revenue for the last quarter is $-0.28
What is the revenue estimate for Soligenix Inc?
According to 3 of Wall street analyst, the revenue estimate of Soligenix Inc range from $0.0 to $0.0
What's the earning quality score for Soligenix Inc?
Soligenix Inc has a earning quality score of A-/59.158146. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Soligenix Inc report earnings?
Soligenix Inc next earnings report is expected in 2026-08-06
What are Soligenix Inc's expected earnings?
Soligenix Inc expected earnings is $0.0, according to wall-street analysts.
Did Soligenix Inc beat earnings expectations?
Soligenix Inc recent earnings of $0.0 does not beat expectations.